Please login to the form below

Not currently logged in
Email:
Password:

KRAS inhibitor

This page shows the latest KRAS inhibitor news and features for those working in and with pharma, biotech and healthcare.

Amgen’s Lumykras receives conditional marketing authorisation from EC

Amgen’s Lumykras receives conditional marketing authorisation from EC

In May 2021, the US Food and Drug Administration (FDA) granted Lumakras accelerated approval, making Amgen’s drug the first of its kind as a KRAS G12C inhibitor to receive regulatory ... Reese added: "Amgen's landmark scientific discovery allowed

Latest news

  • Green light for Amgen’s KRAS inhibitor in the UK Green light for Amgen’s KRAS inhibitor in the UK

    Amgen’s first-in-class KRAS inhibitor sotorasib has been approved in the UK under a deal between the drug maker and NHS England. ... While KRAS has been a focus of research for nearly 40 years, it has proved one of the most challenging therapeutic

  • Amgen aims for first KRAS inhibitor approval in the US Amgen aims for first KRAS inhibitor approval in the US

    The company has filed a new drug application (NDA) with the FDA for the investigational KRAS inhibitor, seeking approval for the treatment of patients with KRAS G12C-mutated locally advanced or ... The CodeBreaK 100 study evaluated the KRAS inhibitor in

  • Merck strengthens KRAS stake with Taiho and Astex partnership Merck strengthens KRAS stake with Taiho and Astex partnership

    Another company looking to crack the KRAS mutation is Amgen, which recently announced some positive data for its pathfinder KRAS inhibitor AMG 510 in KRAS G12C-positive NSCLC. ... Other competitors in the KRAS inhibitor race include Mirati, Boehringer

  • Amgen buys BeiGene stake for $2.7bn to aid push into China Amgen buys BeiGene stake for $2.7bn to aid push into China

    Included in that part of the deal however is Amgen’s much-anticipated KRAS inhibitor  AMG 510, and its bispecific antibody pipeline featuring anti-BCMA candidate  AMG 420.

  • Amgen reveals more data on KRAS drug Amgen reveals more data on KRAS drug

    Unveiled an overall disease control rate of 100%. Amgen has revealed more data for its pathfinder KRAS inhibitor AMG 510, building its case for the drug as a treatment for KRAS ... AMG 510 became the first KRAS inhibitor to show activity in a 35-patient

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....